Back to results
US 2025/0027952 A1Published application
Biomarker database generation and use
AssigneeViome Life Sciences, Inc.
InventorsJohn Blume, Ryan Benz, Jeffrey Jones, William F. Smith, Phong Cun, Bruce Wilcox
Life of this patent
Estimating the term…
Abstract
Databases methods and reagents are disclosed for the generation of large amounts of biomarker data from readily obtained sample such as dried plasma spots, and for uses of such databases in the development of patient categorization or detection of changes in a patient's health status over time.
Claims22
A method for determining colorectal cancer status of a subject, the method comprising:
- obtaining a fluid sample from the subject;
- subjecting the fluid sample to a quantification analysis thereby obtaining a quantification of a plurality of biomarkers comprising alpha-1 antichymotrypsin (AACT), cathepsin D (CATD), carcinoembryonic antigen (CEA), complement component 3 (CO3), complement component 9 (CO9), macrophage migration inhibitory factor (MIF), P-selectin glycoprotein ligand-1 (PSGL), and serine protease (SEPR) protein in the fluid sample;
- and
- inputting, using a computer system, the quantification of the plurality of biomarkers into a model comprising a plurality of parameters to obtain, as output from the model, a colorectal cancer status classification of the subject, wherein the colorectal cancer status classification is one of (i) having colorectal cancer or (ii) not having colorectal cancer.
1 more element
Dependencies are inferred from the claim text.